

# Juan R Cubillos-Ruiz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4439013/publications.pdf>

Version: 2024-02-01

49  
papers

9,794  
citations

186265  
28  
h-index

214800  
47  
g-index

52  
all docs

52  
docs citations

52  
times ranked

16298  
citing authors

#	ARTICLE	IF	CITATIONS
1	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	33
2	Methods and protocols for chemotherapy-induced peripheral neuropathy (CIPN) mouse models using paclitaxel. <i>Methods in Cell Biology</i> , 2022, 168, 277-298.	1.1	2
3	Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. <i>Cancer Discovery</i> , 2022, 12, 1904-1921.	9.4	25
4	Fungal Patterns Induce Cytokine Expression through Fluxes of Metabolic Intermediates That Support Glycolysis and Oxidative Phosphorylation. <i>Journal of Immunology</i> , 2022, 208, 2779-2794.	0.8	4
5	High-Fat Dietâ€“Induced Obesity Alters Dendritic Cell Homeostasis by Enhancing Mitochondrial Fatty Acid Oxidation. <i>Journal of Immunology</i> , 2022, 209, 69-76.	0.8	11
6	Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. <i>Trends in Cancer</i> , 2022, 8, 930-943.	7.4	27
7	Dietary Fructose Alters the Composition, Localization, and Metabolism of Gut Microbiota in Association With Worsening Colitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 525-550.	4.5	58
8	Endoplasmic reticulum stress signals in the tumour and its microenvironment. <i>Nature Reviews Cancer</i> , 2021, 21, 71-88.	28.4	499
9	IRE1â€“XBP1s activation in leukocytes is associated with the level of exposure to paclitaxel in CIPN patients. <i>Journal of Pain</i> , 2021, 22, 581-582.	1.4	1
10	Effects of paclitaxel in mitochondrial function and cellular phenotype in human peripheral blood mononuclear cells and monocytes. <i>Journal of Pain</i> , 2021, 22, 580.	1.4	0
11	Optineurin Guards IFNÎ³ Signaling in Cancer Cells. <i>Cancer Discovery</i> , 2021, 11, 1623-1625.	9.4	1
12	Engineered bacteria recycle tumor metabolic waste to boost immunotherapy. <i>Cell Host and Microbe</i> , 2021, 29, 1725-1727.	11.0	5
13	BTN3A1 governs antitumor responses by coordinating Î±Î² and Î³Î´ T cells. <i>Science</i> , 2020, 369, 942-949.	12.6	83
14	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. <i>Immunity</i> , 2020, 52, 668-682.e7.	14.3	107
15	IRE1â€“XBP1 signaling in leukocytes controls prostaglandin biosynthesis and pain. <i>Science</i> , 2019, 365, .	12.6	91
16	Dendritic Cell Metabolism and Function in Tumors. <i>Trends in Immunology</i> , 2019, 40, 699-718.	6.8	131
17	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. <i>Nature</i> , 2019, 571, 355-360.	27.8	206
18	The impact of endoplasmic reticulum stress responses in dendritic cell immunobiology. <i>International Review of Cell and Molecular Biology</i> , 2019, 349, 153-176.	3.2	15

#	ARTICLE	IF	CITATIONS
19	ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. <i>Nature Communications</i> , 2019, 10, 1280.	12.8	83
20	Tricarboxylic Acid Cycle Activity and Remodeling of Glycerophosphocholine Lipids Support Cytokine Induction in Response to Fungal Patterns. <i>Cell Reports</i> , 2019, 27, 525-536.e4.	6.4	31
21	PolyGlcNAc-containing exopolymers enable surface penetration by non-motile <i>Enterococcus faecalis</i> . <i>PLoS Pathogens</i> , 2019, 15, e1007571.	4.7	24
22	Endoplasmic Reticulum Stress Responses in Intratumoral Immune Cells: Implications for Cancer Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 128-141.	6.8	49
23	Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. <i>Nature Cell Biology</i> , 2018, 20, 332-343.	10.3	1,101
24	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	11.2	4,036
25	IRE1 $\pm$ XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. <i>Nature</i> , 2018, 562, 423-428.	27.8	252
26	Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 969-977.	4.2	22
27	Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer. , 2017, 5, 5.		67
28	Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer. <i>Cell</i> , 2017, 168, 692-706.	28.9	606
29	Endoplasmic Reticulum Stress Sensor IRE1 $\pm$ Enhances IL-23 Expression by Human Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 639.	4.8	33
30	State-of-the-art of regulatory dendritic cells in cancer. , 2016, 164, 97-104.		43
31	Molecular Pathways: Immunosuppressive Roles of IRE1 $\pm$ -XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2016, 22, 2121-2126.	7.0	30
32	Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy. <i>Oncot Immunology</i> , 2016, 5, e1098802.	4.6	15
33	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. <i>Cell</i> , 2015, 161, 1527-1538.	28.9	639
34	IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection. <i>Nature Communications</i> , 2015, 6, 7562.	12.8	58
35	Reprogramming immune responses via microRNA modulation. <i>MicroRNA Diagnostics and Therapeutics</i> , 2014, 1, .	0.0	5
36	Avirulent <i>Toxoplasma gondii</i> Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2013, 73, 3842-3851.	0.9	86

#	ARTICLE	IF	CITATIONS
37	BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1 $\beta$ . <i>EMBO Journal</i> , 2012, 31, 2322-2335.	7.8	99
38	Good things come in small packages. <i>Oncolmunology</i> , 2012, 1, 968-970.	4.6	11
39	Reprogramming Tumor-Associated Dendritic Cells <i>in Vivo</i> Using miRNA Mimetics Triggers Protective Immunity against Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 1683-1693.	0.9	137
40	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. <i>Journal of Experimental Medicine</i> , 2012, 209, 495-506.	8.5	273
41	Antifungal mechanisms by which a novel <i>Pseudomonas aeruginosa</i> phenazine toxin kills <i>Candida albicans</i> in biofilms. <i>Molecular Microbiology</i> , 2010, 78, 1379-1392.	2.5	132
42	CD4+ T Cells Elicit Host Immune Responses to MHC Class II $^+$ Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 5654-5662.	0.8	75
43	Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. <i>Cell Cycle</i> , 2010, 9, 260-268.	2.6	41
44	CD277 is a Negative Co-stimulatory Molecule Universally Expressed by Ovarian Cancer Microenvironmental Cells. <i>Oncotarget</i> , 2010, 1, 329-338.	1.8	62
45	<i>In situ</i> Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells. <i>Cancer Research</i> , 2009, 69, 7329-7337.	0.9	124
46	CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion. <i>Cancer Research</i> , 2009, 69, 6331-6338.	0.9	56
47	Nanomolecular targeting of dendritic cells for ovarian cancer therapy. <i>Future Oncology</i> , 2009, 5, 1189-1192.	2.4	19
48	Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. <i>Journal of Clinical Investigation</i> , 2009, 119, 2231-44.	8.2	177
49	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity. <i>Cancer Research</i> , 2008, 68, 7684-7691.	0.9	105